Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine

New England Journal of Medicine

Volumn 354, Issue 1, 2006, Pages 23-33

  Vesikari, Timo ^a   Matson, David O ^b   Dennehy, Penelope ^c   Van Damme, Pierre ^d   Santosham, Mathuram ^e   Rodriguez, Zoe ^f   Dallas, Michael J ^g   Heyse, Joseph F ^g   Goveia, Michelle G ^g   Black, Steven B ^h   Shinefield, Henry R ⁱ   Christie, Celia D C ^j   Ylitalo, Samuli ^a   Itzler, Robbin F ^g   Coia, Michele L ^g   Onorato, Matthew T ^g   Adeyi, Ben A ^g   Marshall, Gary S ^k   Gothefors, Leif ^l   Campens, Dirk ^m   Karvonen, Aino ^a   Watt, James P ^e   O'Brien, Katherine L ^e   DiNubile, Mark J ^g   Clark, H Fred ⁿ   Boslego, John W ^g   Offit, Paul A ⁿ   Heaton, Penny M ^g   more..

^a UNIVERSITY OF TAMPERE MEDICAL SCHOOL   (Finland)

^b CENTER FOR PEDIATRIC RESEARCH   (United States)

^c RHODE ISLAND HOSPITAL   (United States)

^d UNIVERSITY OF ANTWERP   (Belgium)

^e JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^f UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

^g MERCK RESEARCH LABORATORIES   (United States)

^h KAISER PERMANENTE   (United States)

ⁱ Institute for Vaccine and Pharmacologic Research   (United States)

^j UNIVERSITY OF THE WEST INDIES   (Jamaica)

^k University of Louisville School of Medicine   (United States)

^l UMEÅ UNIVERSITY   (Sweden)

^m SANOFI PASTEUR   (France)

ⁿ UNIVERSITY OF PENNSYLVANIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PENTAVALENT HUMAN BOVINE REASSORTANT ROTAVIRUS VACCINE; PLACEBO; ROTAVIRUS VACCINE; UNCLASSIFIED DRUG;

ADVERSE DRUG REACTION; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EMERGENCY WARD; FEVER; HEALTH SERVICE; HEMATOCHEZIA; HOSPITALIZATION; HUMAN; INFANT; INTUSSUSCEPTION; OUTPATIENT DEPARTMENT; PATIENT MONITORING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SEROTYPE; TREATMENT OUTCOME; VACCINATION; VIRAL GASTROENTERITIS; VIRUS STRAIN; VOMITING;

ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES, VIRAL; CATTLE; DIARRHEA, INFANTILE; DOUBLE-BLIND METHOD; FEMALE; FEVER; GASTROENTERITIS; GASTROINTESTINAL HEMORRHAGE; HEALTH RESOURCES; HOSPITALIZATION; HUMANS; IMMUNOGLOBULIN A; INFANT; INTUSSUSCEPTION; MALE; REASSORTANT VIRUSES; RISK; ROTAVIRUS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; VACCINES, ATTENUATED;

EID: 30044442208     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa052664     Document Type: Article

References (37)

1. Parashar UD, Hummelman EG, Bresee JS, Miller MA, Glass RI. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis 2003;9:565-72.
2. Bresee JS, Glass RI, Ivanoff B, Gentsch JR. Current status and future priorities for rotavirus vaccine development, evaluation and implementation in developing countries. Vaccine 1999;17:2207-22.
3. Moulton LH, Staat MA, Santosham M, Ward RL. The protective effectiveness of natural rotavirus infection in an American Indian population. J Infect Dis 1998;178:1562-66.
4. O'Ryan ML, Matson DO, Estes MK, Pickering LK. Anti-rotavirus G type-specific and isotype-specific antibodies in children with natural rotavirus infections. J Infect Dis 1994;169:504-11.
5. Velazquez FR, Matson DO, Calva JJ, et al. Rotavirus infections in infants as protection against subsequent infections. N Engl J Med 1996;335:1022-8.
6. Velazquez FR, Matson DO, Guerrero ML, et al. Serum antibody as a marker of protection against natural rotavirus infection and disease. J Infect Dis 2000;182:1602-9.
7. Gentsch JR, Woods PA, Ramachandran M, et al. Review of G and P typing results from a global collection of rotavirus strains: implications for vaccine development. J Infect Dis 1996;174:Suppl 1:S30-S36.
8. Santos N, Hoshino Y. Global distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccine. Rev Med Virol 2005;15:29-56.
9. Rotavirus vaccine for the prevention of rotavirus gastroenteritis among children: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 1999;48(RR-2):1-20.
10. Intussusception among recipients of rotavirus vaccine - United States, 1998-1999. MMWR Morb Mortal Wkly Rep 1999;48:577-81.
11. Kramarz P, France EK, Destefano F, et al. Population-based study of rotavirus vaccination and intussusception. Pediatr Infect Dis J 2001;204:10-6.
12. Murphy TV, Gargiullo PM, Massoudi MS, et al. Intussusception among infants given an oral rotavirus vaccine. N Engl J Med 2001;344:564-72.
13. Parashar UD, Holman RC, Cummings KC, et al. Trends in intussusception-associated hospitalizations and deaths among US infants. Pediatrics 2000;106:1413-21.
14. Peter G, Myers MG. Intussusception, rotavirus, and oral vaccines: summary of a workshop. Pediatrics 2002;110(6):e67.
15. Haber P, Chen RT, Zanardi LR, Mootrey GT, English R, Braun MM. An analysis of rotavirus vaccine reports to the vaccine adverse event reporting system: more than intussusception alone? Pediatrics 2004;113(4):e353-e359.
16. Joensuu J, Koskenniemi E, Pang XL, Vesikari T. Randomised placebo-controlled trial of rhesus-human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritis. Lancet 1997;350:1205-9.
17. Joensuu J, Koskenniemi E, Vesikari T. Symptoms associated with rhesus-human reassortant rotavirus vaccine in infants. Pediatr Infect Dis J 1998;17:334-40.
18. Rennels MB, Glass RI, Dennehy PH, et al. Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines - report of the National Multicenter Trial: United States Rotavirus Vaccine Efficacy Group. Pediatrics 1996;97:7-13.
19. Withdrawal of rotavirus vaccine recommendation. MMWR Morb Mortal Wkly Rep 1999;48:1007.
20. Clark HF, Offit PA. Vaccines for rotavirus gastroenteritis universally needed for infants. Pediatr Ann 2004;33:536-43.
21. Glass RI, Bresee JS, Parashar UD, Jiang B, Gentsch J. The future of rotavirus vaccines: a major setback leads to new opportunities. Lancet 2004;363:1547-50.
22. Clark HF, Bernstein DI, Dennehy PH, et al. Safety, efficacy, and immunogenicity of a live, quadrivalent human-bovine reassortant rotavirus vaccine in healthy infants. J Pediatr 2004;144:184-90.
23. Vesikari T, Clark HF, Offit PA, et al. The effect of dose and composition of a pentavalent rotavirus vaccine (RotaTeq) upon safety, efficacy, and immunogenicity in healthy infants. Presented at the 22nd annual meeting of the European Society for Pediatric Infectious Diseases (ESPID), Tampere, Finland, May 26-28, 2004.
24. Chang EJ, Zangwill KM, Lee H, Ward JI. Lack of association between rotavirus infection and intussusception: implications for use of attenuated rotavirus vaccines. Pediatr Infect Dis J 2002;21:97-102.
25. Rennels MB, Parashar UD, Holman RC, Le CT, Chang HG, Glass RI. Lack of an apparent association between intussusception and wild or vaccine rotavirus infection. Pediatr Infect Dis J 1998;17:924-5.
26. Heaton PM, Goveia MG, Miller JM, Offit P, Clark HF. Development of a pentavalent rotavirus vaccine against prevalent serotypes of rotavirus gastroenteritis. J Infect Dis 2005;192:Suppl 1:S17-S21.
27. Gilchrist MJ, Bretl TS, Moultney K, Knowlton DR, Ward RL. Comparison of seven kits for detection of rotavirus in fecal specimens with a sensitive, specific enzyme immunoassay. Diagn Microbiol Infect Dis 1987;8:221-8.
28. Dolan KT, Twist EM, Horton-Slight P, et al. Epidemiology of rotavirus electropherotypes determined by a simplified diagnostic technique with RNA analysis. J Clin Microbiol 1985;21:753-8.
29. Jennison C, Turnbull BW. Group sequential methods with applications to clinical trials. Boca Raton, Fla.: Chapman & Hall/CRC, 2000.
30. DiStefano DJ, Kraiouchkine N, Mallette L, et al. Novel rotavirus VP7 typing assay using a one-step reverse transcriptase PCR protocol and product sequencing and utility of the assay for epidemiological studies and strain characterization, including serotype subgroup analysis. J Clin Microbiol 2005;43:5876-80.
31. Laboratory-based surveillance for rotavirus - United States, July 1996-June 1997. MMWR Morb Mortal Wkly Rep 1997;46:1092-4.
32. LeBaron CW, Lew J, Glass RI, Weber JM, Ruiz-Palacios GM. Annual rotavirus epidemic patterns in North America: results of a 5-year retrospective survey of 88 centers in Canada, Mexico, and the United States. JAMA 1990;264:983-8.
33. Vesikari T, Rautanen T, Von Bonsdorff CH. Rotavirus gastroenteritis in Finland: burden of disease and epidemiological features. Acta Paediatr Suppl 1999;88:24-30.
34. Duffy LC, Byers TE, Riepenhoff-Talty M, La Scolea LJ, Zielezny M, Ogra PL. The effects of infant feeding on rotavirus-induced gastroenteritis: a prospective study. Am J Public Health 1986;76:259-63.
35. Ward RL, Knowlton DR, Zito ET, Davidson BL, Rappaport R, Mack ME. Serologic correlates of immunity in a tetravalent reassortant rotavirus vaccine trial: US Rotavirus Vaccine Efficacy Group. J Infect Dis 1997;176:570-7.
36. Coffin SE, Moser CA, Cohen S, Clark HF, Offit PA. Immunologic correlates of protection against rotavirus challenge after intramuscular immunization of mice. J Virol 1997;71:7851-6.
37. Rodriguez WJ, Kim HW, Brandt CD, et al. Sequential enteric illnesses associated with different rotavirus serotypes. Lancet 1978;2:37.